Tanner Pharma Group and Biodexa Launch Global Early Access Program for FAP Patients

Contributed by: Business Wire

Logo

Tags

Oncology

Health

Diabetes

Other Health

General Health

Pharmaceutical

Biotechnology

Tanner Pharma Group

More Like This

PR Newswire associated0

Telix to Add FAP-Targeting Candidates to Theranostic Pipeline

GlobeNewswire associated0

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks

Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors

PR Newswire associated0

Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories

Vertex Announces Key Advancements Across Kidney Portfolio

Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function

PR Newswire associated0

Pierre Fabre Laboratories and RedRidge Bio Announce a Drug Discovery and Co-development Partnership

PR Newswire associated0

TFS HealthScience Expands Collaboration with Oncomatryx for Phase Ib Trial of OMTX705 for Pancreatic Cancer